Full Press Release Details
IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma.
IDYA
IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma
Key Takeaway: IDEAYA Announces IDMC Recommendation of Move Forward Dose in Part 2a of Registration Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA A2 Negative Metastatic Uveal Melanoma